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Abstract
Background: Prior research suggests that 60-74% of males and 16-45% of females with fragile X
syndrome (FXS) meet criteria for autism spectrum disorder (ASD) in research settings. However,
relatively little is known about the rates of clinical diagnoses in FXS and whether such diagnoses are
consistent with those performed in a research setting using gold standard diagnostic tools. Method: This
study explored whether boys and girls with FXS met criteria for ASD in a research setting using the
Autism Diagnostic Observation Schedule (ADOS; Lord et al. 2001) and the Autism Diagnostic
Interview-Revised (ADI-R; Lord et al. 1994), and then compared these data with the frequency of parentreported clinical diagnoses. We also examined child and family characteristics as potential diagnostic
predictors across settings. Participants included 35 females and 51 males with FXS (mean age: 10 years),
who were from Eastern and Midwestern regions of the United States. Results: About half of the children
met criteria for ASD on either the ADOS or ADI-R, with ASD occurring three times more frequently in
males than females (~75% versus ~25%). In contrast, ~25% of participants of both genders had received a
clinical diagnosis of ASD. While cognitive and language skills predicted diagnostic outcome on the
ADOS and ADI-R, these skills did not predict clinical diagnoses. Executive functions predicted clinical
diagnoses, but not diagnoses per the ADOS or ADI-R. Conclusions: ASD in FXS may be underdiagnosed in clinical/educational settings, which raises questions regarding access to ASD-related
services.
Keywords: autism, fragile X syndrome, autism spectrum disorder; ADOS; ADI-R

AUTISM IN FRAGILE X SYNDROME

2

Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability, and the
most common known monogenic disability associated with autism spectrum disorder (ASD; Cohen et al.
2005). FXS occurs in 1 in 2,500 individuals (Hagerman 2008, Fernandez-Carvajal et al. 2009) and is
caused by a mutation in the Fragile X Mental Retardation 1 (FMR1) gene. This mutation prevents the
production of Fragile X Mental Retardation Protein (FMRP), a protein that is essential for brain
development, giving rise to the neurocognitive phenotype that defines FXS (Loesch et al. 2004, Tassone
et al. 1999). Notably, there is significant overlap in the behavioral phenotypes of FXS and ASD,
including shared social and communication deficits (Hagerman and Hagerman 2002). While reported
rates vary according to diagnostic method and participant characteristics (e.g., age, gender), it is estimated
that 25-50% of males with FXS meet diagnostic criteria for autistic disorder in a research setting, which is
defined by social and communication impairments, and the presence of restricted/repetitive behaviors
(American Psychological Association 1994). Rates are much higher when considering the number of
males who meet diagnostic criteria for ASD (i.e., an umbrella term, including autistic disorder as well as
milder variants such as pervasive developmental disorder-not otherwise specified, or PDD-NOS). Sixty to
seventy-four percent of males with FXS meet criteria for ASD in a research setting (Harris et al. 2008,
Clifford et al. 2007, Rogers et al. 2001). Reported rates in females with FXS are lower than those in
males, with 13-20% meeting criteria for autistic disorder, and 45% for ASD (Clifford et al. 2007, Hall et
al. 2008). See Table 1 for detailed review of reported rates of ASD in FXS.
While several research groups have examined the rate of ASD comorbidity in FXS within a
research context, much less is known about the rate at which individuals with FXS are diagnosed with
ASD in real-life clinical or educational settings. Our knowledge of this topic is limited to one report by
Bailey and colleagues (2008), who found that ~45% of males and ~15% of females were reported to have
been diagnosed with and/or treated for autism in a large, nationally-representative survey of families of
individuals with FXS. While these figures are generally consistent with the rates of research-derived
diagnoses of autistic disorder, they are considerably lower than rates reported for ASD. Thus, questions
remain regarding clinical ASD diagnostic practices and how these diagnoses might agree with estimates
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using gold standard diagnostic tools. Better understanding of ASD diagnostic practices in FXS has
important implications for clinical practice, given that diagnostic classification may dictate the
type/intensity of services that a child will qualify for in certain medical and educational settings.
Research strongly suggests that ASD comorbidity has a significant impact on functional
outcomes for individuals with FXS. Children with FXS and co-occurring ASD present with a behavioral
phenotype that is distinct from that of FXS without ASD, and which is characterized by more significant
cognitive impairment (Bailey et al. 2000, Bailey et al. 2001, Clifford et al. 2007, Loesch et al. 2007,
Dissanayake et al. 2009, Rogers et al. 2001), greater social impairment (Hernandez et al. 2009, Kau et al.
2004, Budimirovic et al. 2006, Kaufmann et al. 2004, Hessl et al. 2006), poorer adaptive functions
(Rogers et al. 2001, Kau et al. 2004), increased likelihood for developing secondary medical conditions
(Garcia-Nonell et al. 2008), and, according to some reports, decreased receptive language skills (Lewis et
al. 2006, Rogers et al. 2001). Furthermore, it appears that ASD symptoms in FXS remain relatively stable
over time (Hernandez et al. 2009, Sabaratnam et al. 2003), suggesting that children are not likely to
“grow out of” autistic behaviors without specialized intervention. Given evidence that individuals with
FXS and comorbid ASD are at risk for suboptimal outcomes, ASD comorbidity should be a key factor in
determining the type and intensity of interventions for this population. Further, because individuals with
FXS and ASD may present with unique phenotypic profiles, it is essential to consider the presence of
ASD features in studies of behavior, brain, and genetic effects in FXS.
Better understanding of the use of ASD diagnostic tools in FXS is also critical for research. It is
unclear how different diagnostic tools might be better able to tease apart these complex phenotypes of
FXS, and how the use of different tools might influence study results. For example, in a longitudinal
study of 56 boys with FXS, Hernandez et al. (2009) found that the Autism Diagnostic Observation
Schedule (ADOS; Lord et al. 2001) over-identified children with FXS as having ASD as compared to the
Autism Diagnostic Interview-Revised (ADI-R; Lord et al. 1994) and the Diagnostic and Statistical
Manual of Mental Health Disorders (DSM-IV; American Psychological Association 1994). On the other
hand, in a different study of 63 boys, Harris et al. (2008) suggested that the ADI-R over-identified ASD in
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FXS, presumably because of its focus on behaviors during early childhood, when autistic-like symptoms
may be most prominent. Clarifying best practices for diagnosing ASD within the context of FXS will
allow for more efficient and accurate phenotypic characterization, which is a foundational step in
answering broader questions regarding the role of ASD in biobehavioral pathways of FXS.
Recently, FXS has been proposed as a genetic model for informing the etiological basis of ASD
(e.g., Abrahams and Geschwind 2010, Belmonte and Bourgeron 2006, Hagerman et al. 2011). As a
single-gene disorder that is associated with significant genetic risk to ASD, FXS provides an opportunity
to link a known genetic mutation with core behavioral and biological features associated with ASD.
FMR1 interacts with other background genes that are involved in ASD, thereby reducing the genetic
threshold needed to produce ASD (Bailey et al. 2001, Rogers et al. 2001). A number of molecular-genetic
studies support this hypothesis with direct evidence indicating that the protein that is encoded by FMR1,
FMRP, is involved in the regulation of a number of autism susceptibility genes (Iossifov et al. 2012,
Darnell et al. 2011, Darnell and Klann 2013). For example, a significant proportion of autism candidate
genes are now understood to interact with FMRP (Darnell and Klann 2013), and a number of proteins that
are implicated in idiopathic ASD (including SHANK3, CYFIP1, PTEN, and NRXNI) are regulated by
FMR1-associated mechanisms such as FMRP and components of the mGluR signaling pathway (Bagni et
al. 2012, Iossifov et al. 2012, Darnell et al. 2011, Darnell and Klann 2013, Hagerman et al. 2010, De
Rubeis and Bagni 2011). Clarifying the rate at which ASD occurs in FXS (and how diagnostic practices
impact this estimate) will contribute to our understanding of the coupling between the FMR1 mutation
and the development of ASD.
This study examined rates of ASD among boys and girls with FXS by comparing the children’s
history of clinical diagnoses of ASD with diagnostic assessments conducted using gold standard
instruments in a controlled research setting. The concordance of ASD status across diagnostic methods
was examined to inform diagnostic patterns that have implications for clinical and research practices in
FXS. Finally, potential predictors of ASD diagnoses were examined, in order to shed light on factors that
might influence the identification of ASD in FXS.
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Methods

Participants
Eighty-six children with FXS participated in the study (51 boys and 35 girls). The average age of
all participants was 10.77 years (SD = 3.64), with a mean age of 11.75 (SD = 3.11) for boys and 9.38 (SD
= 3.91) for girls. The children who participated in this study were recruited from a larger, longitudinal
study of language in FXS (XX). Children were selected for participation from the larger pool if they had
been administered the Family History Interview (which assesses clinical diagnostic history) and either of
the gold standard diagnostic tools, all described below. Participants were ascertained through medical
facilities and parent groups, and through the XX. Recruitment was based in the Eastern and Midwestern
regions of the United States. As inclusionary criteria for the larger study, all participants were verbal
(using three-word phrases) and were native speakers of English. See Table 2 for demographic
characteristics.
Procedures
Assessments were administered within the context of the broader research protocol. While all
child-based measures were administered concurrently, it was not always possible to administer the
caregiver-report measures (the Family History Interview [Bolton et al., 1994] and the Autism Diagnostic
Interview-Revised [ADI-R; Lord et al., 1994], described below) concurrently with the child assessments.
An average of 11 months passed between administration of the Family History Interview and the child
assessments, and an average of six months between the ADI-R and child assessments. Procedures were
approved by the Institutional Review Boards of XX.
ASD Diagnostic Procedures
Gold standard ASD assessments. Two ASD diagnostic assessments were administered: the
Autism Diagnostic Interview-Revised (ADI-R; Lord et al. 1994) and the Autism Diagnostic Observation
Schedule (ADOS; Lord et al. 2001). In the ADI-R, an examiner leads the caregiver through an interview
designed to elicit descriptions of the child’s social, communicative, and repetitive/restricted/stereotyped
behaviors. The diagnostic algorithm is based on symptoms exhibited during early childhood (focused on
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4-5 years of age), and yields a diagnosis of “autism” or “no autism”. In order to meet diagnostic criteria
for “autism” participants must meet thresholds for four symptom domains: social interaction,
communication, restricted/repetitive/stereotyped behavior, and onset before three years. The ADI-R was
coded by examiners who had achieved research reliability per the standards of the instrument developers.
The second gold standard diagnostic instrument, the ADOS, bases diagnoses on direct
observation of behaviors during a play-based interaction. All examiners were trained to reliably code the
ADOS either through training with the developers of the ADOS or through intra-lab reliability, in
accordance with the standards of the instrument developers. Classification of “autism”, “autism spectrum”
and “no autism” was determined using the revised ADOS algorithms (Gotham et al. 2007), which
consider information from all three domains of the autism triad in determining diagnostic status (whereas
the original algorithms did not take into account restricted/repetitive features). Individuals who met
diagnostic thresholds for either “autism” or “autism spectrum” were considered “positive” for an ASD
diagnosis. This strategy was chosen as it is consistent with the DSM-5 diagnostic criteria for ASD, which
collapse autistic disorder and PDD-NOS into the single category, “autism spectrum disorder” (American
Psychiatric Association 2013). ADOS diagnostic information was missing for one male, who was unable
to complete the assessment due to problem behaviors.
Clinical diagnoses of ASD. Clinical diagnoses of ASD were determined via caregiver report
within the context of an abbreviated Family History Interview (Bolton et al. 1994), which was most often
completed by the participant’s mother prior to the ADI-R. Within the context of a broader interview about
family structure and medical histories, caregivers were asked whether anyone in their family (including
their child) had a diagnosis of autism or autism spectrum disorder. While the Family History Interview is
a well-established method for evaluating autism family history, reports are based solely on caregiver
recollection of whether the child had been evaluation and what the outcome was. Therefore, two
circumstances might apply to children who were reported to be negative for a clinical diagnosis: (1) the
child had been evaluated but did not meet criteria for an ASD diagnosis or (2) the child had never been
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referred/evaluated for ASD diagnostics. Children whose caregivers reported a diagnosis of autism, autism
spectrum disorder, or PDD-NOS were considered “positive” for a clinical diagnosis of ASD.
Predictors of ASD Diagnosis
Cognitive and language ability. Nonverbal cognitive ability was assessed using the Leiter
International Performance Scale-Revised Brief IQ (Leiter-R; Roid and Miller 1997). Receptive and
expressive language ability were also measured, with the Peabody Picture Vocabulary Test-III (PPVT;
Dunn and Dunn 1997) and the Expressive Vocabulary Test (EVT; Williams 1997), respectively. Age
equivalent scores were computed for each measure from published norms.
Executive functions. The Behavior Rating Inventory of Executive Function-Preschool Version
(Brief-P; Gioia et al. 2000) was used as a caregiver-report scale of executive functions such as inhibition,
shifting emotional control, and planning/organizing. The preschool version was administered as the
younger items were judged to be more closely aligned with the mental age of the participants. Because a
number of participants were thus outside of the age range of the normative sample for the Brief-P, raw
scores of the Global Executive Composite were used in analysis.
Behavioral and emotional problems. The Child Behavior Checklist-1 ½-5 years (CBCL;
Achenbach and Rescorla 2000) was completed by the primary caregiver to assess child maladaptive
behavioral and emotional problems. The total score was examined, which includes a range of symptoms
such as social problems, anxiety, and destructive behavior. Like the Brief-P, the younger version of the
CBCL was administered as the items were thought to be more applicable to the functioning level of the
participants. Raw scores were used, which is recommended by the test publishers (Achenbach and
Rescorla 2000).
Socioeconomic factors. Maternal education level (in years) and household income (<39k, 40-79k,
<80k) were collected using a standard demographic survey.
Analysis strategy
Descriptive statistics were used to examine the rates of ASD diagnoses. Gender differences in the
rates of ASD were tested using Fisher’s exact test. The concordance of clinical and gold standard
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diagnoses was determined by calculating point-to-point “agreement” for each participant. The term
“agreement” is used throughout to describe the concordance of the various ASD diagnostic methods.
However, it should be noted that the Family History Interview does not include extensive clinical
evaluation. As such, reports of clinical diagnostic status were based solely on caregiver recollection of
whether children had been evaluated and what the outcome was. Therefore, using the Family History
Interview we were unable to determine whether a “negative” agreement might in some cases reflect
children never having been evaluated for ASD. Finally, the contribution of the predictor variables to
diagnostic outcomes was examined with a series of binary logistic regression models. Because children
who are older may have had more opportunities to have been evaluated for ASD (Bailey et al. 2008),
chronological age was covaried in the models to facilitate comparison across genders.
Results
Rates of ASD Across Diagnostic Methods
Using the stringent criterion of meeting cut-off on both the ADI-R and the ADOS, 43.5% of
participants met criteria for ASD overall. Sixty percent of the males met the stringent criteria, and 14.3%
of the females (see Figure 1). Using the ADI-R only, just over half of the sample (53.5%) met criteria for
ASD. Among the males, 74.5% met ADI-R cut-offs, while 22.9% of the females did. Slightly more
participants (56.5%) scored above ADOS diagnostic cut-offs. Seventy-eight percent of the males and
25.7% of the females met ADOS criteria. Significant gender effects were detected for the rate of
diagnoses per the ADOS, ADI-R, and ADI-R+ADOS (ps < .001), with more males diagnosed with ASD
than females. Twenty-five percent of children (25.5% of males and 22.9% of females) had been
diagnosed with ASD clinically, and no gender effects were detected (p = .494).
Agreement Among Diagnostic Methods
Agreement between clinical diagnosis and the ADI-R+ADOS. Using stringent research
classification (meeting cut-offs for both the ADI-R and the ADOS), the agreement with clinical diagnosis
was 68% in the full sample. More individuals were identified as positive for ASD on the ADI-R+ADOS
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than by clinical diagnosis. Sixty percent of individuals who met criteria on the ADI-R+ADOS did not
have a clinical diagnosis, whereas 30% who had a clinical diagnosis did not meet ADI-R+ADOS criteria.
For males, the ADI-R+ADOS classification was concordant with clinical diagnoses 56% of the
time. Of the 30 males who were positive on the ADI-R+ADOS, 66.6% had not received a clinical
diagnosis. Two males had received a clinical diagnosis without also meeting diagnostic criteria on the
ADI-R+ADOS. For females, agreement was 85.7%. One of the five females who were identified with the
ADI-R+ADOS did not have clinical diagnoses (20%), and 50% of the females had a clinical diagnosis yet
did not meet thresholds on both the ADI-R and ADOS.
Agreement between clinical diagnosis and the ADI-R. Agreement between the ADI-R and
caregiver reports of clinical diagnoses was 68.6% overall (see Table 3). More individuals were identified
as positive on the ADI-R than by clinical diagnosis; 55.6% of the individuals who were identified with
the ADI-R did not have a clinical diagnosis (whereas 5% of those who had a clinical diagnosis did not
meet ADI-R thresholds). For males, clinical diagnoses agreed with the ADI-R in 51% of cases, with
discrepancies related to higher identification with the ADI-R than clinical diagnosis (65.8% of the males
who were identified with the ADI-R did not have a clinical diagnosis). For females, overall agreement
was 94.3%; 12.5% were positive on the ADI-R but not clinically and 12.5% had a clinical diagnosis yet
did not meet ADI-R criteria.
Agreement between clinical diagnosis and the ADOS. Within the full sample, 52.9% of the
caregiver-reported clinical diagnoses agreed with ADOS classification. Agreement was lower among
males than females (40% versus 74.3%, respectively). Diagnostic disagreements were most often related
to higher identification rates with the ADOS (70.8% of children who met ADOS criteria did not have a
clinical diagnosis). Among males, 74.4% met criteria on the ADOS but did not have a clinical diagnosis,
whereas 16% had a clinical diagnosis but did not reach ADOS thresholds. Of the females, 55.6% were
positive on the ADOS yet did not have a clinical diagnosis. Fifty percent of the females who had received
a clinical diagnosis did not meet ASD criteria (see Table 3).

AUTISM IN FRAGILE X SYNDROME

10

Agreement between ADI-R and ADOS. The ADI-R and ADOS agreed 76.5% of the time in the
full sample. Twenty-two percent of children who were positive on the ADI-R were not identified with the
ADOS, and 27.1% of those who were positive on the ADOS were negative on the ADI-R. ADOS and
ADI-R agreement was lower for males (68%) than females (80%). Discrepancies did not appear to be
related to one instrument over-identifying ASD in comparison to the other; see Table 4).
Predictors of ASD Diagnosis
Cognitive and language predictors. In the full sample, nonverbal mental age, receptive
vocabulary, and expressive vocabulary were significant predictors of ADI-R and ADOS diagnoses (with
the odds of having ASD decreasing as each of these skills increased). Mental age, receptive vocabulary,
and expressive vocabulary did not predict clinical diagnoses (see Table 5). No significant predictors of
ASD emerged among the subgroups of males or females, although there was a trend for nonverbal mental
age as a predictor of ADI-R status among females (OR= .47, p = .088).
Behavioral predictors. Executive functions and behavioral/emotional control were not significant
predictors of diagnostic outcome on the ADOS or ADI-R; however, there were trends for increased
likelihood of a diagnosis on the ADI-R as behavioral/emotional problems increased, and for increased
likelihood of ADOS diagnosis with greater executive impairment (see Table 6). Executive function
significantly predicted caregiver-reported clinical diagnoses, with increased odds of having a diagnosis
with greater executive impairment after controlling for age (OR = 1.04, p = .013). In the gender
subgroups, executive function significantly predicted clinical diagnoses in males but not females.
Behavioral/emotional problems did not significantly predict ADOS or ADI-R outcomes, although a trend
was detected for increased odds of a clinical diagnosis with more significant behavioral/emotional
difficulties (OR = 1.02, p = .062).
Socioeconomic predictors. Neither maternal education level nor household income significantly
predicted ADI-R, ADOS or clinical diagnoses. There was, however, a trend for decreased likelihood of
diagnosis per the ADOS as income level increased from the <40k to 40-79k income bracket (OR = 11.37,
p = .063).
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Discussion

This study examined the agreement between ASD diagnoses derived from clinical and research
settings in boys and girls with FXS and examined potential correlates of ASD diagnoses. While high
agreement was observed between the ADOS and ADI-R administered as part of a research protocol, there
was poor agreement between these measures and caregiver-reported clinical diagnoses; over half of the
children who met diagnostic criteria for ASD in the research protocol were not identified as having ASD
clinically.
Approximately 65% of the boys and 20% of the girls who met criteria for ASD as part of the
research evaluation had not been previously identified as having ASD in other settings, according to
caregiver report. This suggests that a significant proportion of children with FXS who would meet
diagnostic criteria for ASD are not identified clinically (although it is unknown whether this is due to
under-referral of children with FXS for ASD diagnostics versus false negatives in clinical evaluation).
Boys in particular were likely to meet criteria for ASD in the research setting despite being negative for a
clinical diagnosis, suggesting that under-diagnosis may be common among boys with FXS. While more
research is needed to investigate this finding, it is possible that ASD comorbidity is more likely to be
overlooked in boys with FXS, who are generally more affected than girls and may be more likely to
receive services under a diagnosis of “intellectual disability” as opposed to “ASD”. Because girls with
FXS are less affected, the presentation of ASD among girls may also stand out more clearly, drawing the
attention of caregivers and health/educational professionals.
Under-diagnosis of ASD in individuals with FXS has important implications for services, given
that in many settings diagnostic classification precedes (and often dictates) the type/intensity of services.
Because diagnostic classification serves as a guide for health practitioners and educators, professionals
who are aware of ASD comorbidity might be better able to tailor treatment towards ASD-related
symptoms. For example, health care providers who are aware of ASD comorbidity might be more
watchful of secondary medical conditions that are more common in FXS with co-occurring ASD, such as
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seizures (Garcia-Nonell et al. 2008). Overall, more accurate diagnostic information can only assist in
making informed medical/educational decisions.
While findings support a clear trend of higher identification with the ADOS/ADI-R as compared
to clinical diagnoses, there was a subset of children who were identified clinically but did not meet
criteria for ASD in the research setting. This pattern appeared to be specific to the ADOS, which failed to
identify 30% of the children with a clinical ASD diagnosis, rather than the ADI-R (which missed less
than 1% of children). In particular, the ADOS appeared to be less sensitive in identifying ASD in females,
missing half of the females who had received a clinical diagnosis. Additional research is needed to
determine the cause of this pattern. It is possible that females with FXS are adept at compensating for
social difficulties during short-lived interactions such as the ADOS and therefore do not show sufficient
features to meet diagnostic criteria on this measure, whereas clinical diagnoses and the ADI-R are able to
incorporate more comprehensive information regarding the child’s behaviors in everyday settings.
In attempts to inform potential reasons for under-diagnosis, this study explored factors that may
make an individual more likely to be referred, evaluated, and eventually diagnosed with ASD. Contrary to
expectations, we found that mental age and language skills did not predict clinical diagnoses (although
they did predict ADOS/ADI-R diagnoses, as would be expected given that ASD comorbidity in FXS is
associated with greater impairment). Perhaps health professionals expect language and cognitive delays as
a part of FXS, and therefore are likely to overlook red flags for ASD when a child is also struggling with
language and cognitive skills. Rather, clinical diagnoses became more likely as children showed greater
deficits in executive functions. This suggests that regulatory management deficits (e.g., impulsivity,
cognitive inflexibility) may be salient features that prompt health professionals to assess for ASD.
Surprisingly, socioeconomic variables did not predict clinical diagnoses (families with more resources
would be expected to have better access to services). Perhaps this study was under-powered to detect
effects; or, the income categories may have been too broad to capture subtle trends. Other factors not
measured in this study, such as personal beliefs about the nature of ASD in FXS, may also have a
substantial influence on diagnostic patterns. Anecdotally, many caregivers commented during the clinical
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interview that although their child shows symptoms that are consistent with ASD, their child does not
have ASD because such symptoms are caused by FXS. The question of whether ASD within FXS
represents “true” autism is a question that researchers, clinicians, and families alike have grappled with,
and one that has immense implications for diagnosis and intervention. Stakeholders who hold the view
that ASD symptoms are not independent from FXS may be less likely to pursue ASD-related services.
Findings were generally consistent with prior reports. In females, this study detected rates of 2025% across the ADOS and ADI-R, which is consistent with prior estimates ranging from 3-45% (Hall et
al., 2008, Clifford et al., 2007; McDuffie et al., 2010). For males, the rates detected with the ADOS were
comparable to existing studies, whereas the rates detected with the ADI-R were elevated, with
approximately three-fourths of the boys meeting diagnostic thresholds on the ADI-R, in contrast to 4550% in prior research (Harris et al., 2008; Rogers et. al. 2001). Differences in participant characteristics
may account for discrepant findings; this study excluded nonverbal individuals, which may have led to
the inclusion of a subgroup of children who were more likely to meet ADI-R diagnostic thresholds. In
fact, Kaufmann et al. (2004) found that better expressive language skills predicted more severe ADI-R
scores in boys with FXS. A report by McDuffie et al. (2010) also examined a group of verbal boys with
FXS and found that 63% met diagnostic criteria on the ADI-R.
In general, the ADOS and the ADI-R yielded comparable rates of ASD. Within individual
participants, agreement between the ADOS and ADI-R was high (~70% for boys and ~80% for girls),
supporting their use with individuals with FXS. It is unclear how the ADOS/ADI-R agreement detected in
this study compares with that of prior research, as no studies to our knowledge have reported
concordance/discordance of the two measures in FXS. That is, prior studies have not reported the
diagnostic agreement across tools at the participant level, although a number of studies have compared
overall diagnostic rates per instrument. Even if both instruments detected similar group rates of ASD, this
does not necessarily indicate that both tools identified the same participants as having ASD.
While this study provides a starting point for understanding ASD diagnostic practices in FXS, it
is still unclear why ASD in FXS appears to be under-diagnosed (e.g., whether the low rates of clinical
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diagnoses were caused by breakdowns in the referral process versus false-negatives in clinical
evaluation). As noted previously, the clinical diagnoses did not take into account whether participants had
been evaluated for ASD--it is possible that some children were simply never referred for diagnostic
evaluation. Along these lines, clinical diagnoses in this study reflect whether caregivers believed that their
child had ASD, disregarding the setting from which the child’s diagnosis was received. Future studies
investigating the sources of clinical diagnoses (medical, educational, research, or otherwise) would be
invaluable in understanding diagnostic practices in FXS. Nonetheless, caregiver beliefs about their child’s
ASD status are likely to be clinically meaningful (regardless of the source of the diagnosis), as caregivers
who believe that their child has ASD may seek out services that differ in type or intensity. Currently, it is
unknown whether knowledge of ASD-status leads to improved educational and medical outcomes for
children with FXS. Research investigating the functional implications of clinical ASD diagnoses in FXS
is needed to understand the potential consequences of clinical under-diagnosis of ASD.
A limitation of this study is that only verbal individuals with FXS were studied, which might
limit generalizability. Findings should also be replicated in different regions of the US and other
countries, where diagnostic practices may vary. This study is also limited to examination of a single time
point and cannot account for potential changes in the presentation of ASD across the lifespan. Finally, this
study operated under the assumption that the ADOS and ADI-R represented the participant’s “true”
diagnostic classification. Although these tools are widely used with high sensitivity and specificity, they
are not comprehensive and should be used within the context of a broader clinical assessment.
In conclusion, this study identified rates of ASD comorbidity in FXS at about 75% for males and
25% for females, using gold-standard diagnostic tools. Strikingly, a significant proportion of children
with FXS who were identified as having ASD in the research setting had not been identified clinically.
Results may have implications both for clinical practice and research, in that defining clinically distinct
groups of individuals with FXS allows for tailored intervention and contributes to the identification of
ASD-associated pathways that become disrupted in the presence of the FMR1 mutation.
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Table 1. Reported Rates of ASD among Individuals with FXS
Authors (Year)

Bailey, Raspa,
Olmsted, & Holiday
(2008)

Sample
characteristics
976 males; 259
females (national
survey)

6-30+ years (M age
not reported)
Clifford,
Dissanayake, Bui,
Huggins, Taylor, &
Loesch (2007)

33 males; 31
females
(ascertained via
clinical referrals)

Diagnostic procedures

Detected rates of Autism

Caregivers asked: “Has this
child ever been diagnosed or
treated by a medical
professional for any of the
following conditions…
autism?”

Males: 46%

Participants who scored above
SCQ thresholds were
administered the ADI-R &
ADOS

Males: 36% on ADI-R; 67% on ADOS
for autism/spectrum; 27% on ADI-R+
ADOS autism/spectrum

Females: 16%

Females: 3% on ADI-R; 13% on
ADOS for autism/spectrum; 13% on
ADI-R+ ADOS autism/spectrum
5-60 years (M 23.2)
Garcia-Nonell,
Ratera, Harris,
Hessl, Ono, et al.
(2008)

90 males

Hall, Lightbody, &
Reiss (2008)

31 males; 29
females

ADOS, DSM-IV

63% on ADOS for autism/spectrum +
DSM-IV for autism or PDD-NOS

3-25 years (M ~8)
ADOS

Males: 74% for autism/spectrum
Females: 45% for autism/spectrum

5-20 years (M ~13)
Harris, Hessl,
63 males
Bacalman, GoodlinJones, Ferranti, et al.
(2008)
2-19 years (M 7.9)

ADI-R, DSM-IV & ADOS

49% on ADI-R; 49% on ADOS for
autism/spectrum; 35% on DSM-IV for
autism; 59% on DSM-IV for PDDNOS; 27% on ADI-R+DSMIV+ADOS autism/spectrum

Hernandez,
Feinberg, Vaurio,
Passanante,
Thompson, et al.
(2009)

56 males

ADI-R, DSM-IV

43% on ADI-R+DSM-IV

Rogers, Wehner, &
Hagerman (2001)

23 males; 1 female
(ascertained via

ADOS, DSM-IV, & ADI-R
(used reduced cut-off scores

46% on ADI-R; 33% on ADI-R+
DSM-IV+ ADOS autism/spectrum

Age range not
reported (M 4.7
years
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for the ADI-R repetitive
behavior domain)

2-4 years (M 2.9)
Note: ADOS rates are reported for children who met criteria for either “autism” or “autism spectrum”. ADI-R rates
report the percentage of children who met criteria of “autism” (the ADI-R does not provide diagnostic cut-offs for
“autism spectrum”). ADOS=Autism Diagnostic Observation Scale; ADI-R=Autism Diagnostic Interview- Revised;
SCQ=Social Communication Questionnaire; DSM-IV=American Psychiatric Association Diagnostic and Statistical
Manual- 4th Edition; PDD-NOS=Pervasive developmental disorder-not otherwise specified.
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Table 2. Participant Characteristics
Full sample
(N = 86)
Age in years
M (SD)
Range
Mental age
M (SD)
Range
FSIQ
M (SD)
Range
Maternal education
M (SD)
Race
White
African American
Other
Household Income
<20k
40-79k
>80k

Males
(n = 51)

Females
(n = 35)

10.77 (3.64)
4.23-17.90

11.75 (3.11)
6.47-17.90

9.38 (3.91)
4.23-15.87

5.79 (1.90)
3.50-14.92

5.11 (0.60)
3.50-6.67

6.77 (2.60)
3.92-6.77

64.22 (24.05)
36.00-124.00

49.94 (12.99)
36.00-79.00

84.63 (21.25)
38.00-124.00

15.72 (2.06)

15.79 (2.13)

15.62 (2.00)

79.1%
5.8%
9.3%

84.3%
3.9%
7.8%

71.4%
8.6%
11.4%

7.7%
20.5%
70.8%

5.7%
22.9%
71.4%

7.7%
21.5%
70.8%
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Table 3. Number of Children Identified as Positive or Negative for ASD via Gold Standard Diagnostic
Tools in Comparison to Clinical Diagnoses
Clinical Diagnosis
Full Sample

Males

Females

Pos.

Neg.

Total

Pos.

Neg.

Total

Pos.

Neg.

Total

Positive

14

21

35

10

20

30

4

1

5

Negative

6

44

50

2

18

20

4

26

30

Total

20

65

85

12

38

50

8

27

35

Positive

20

26

46

13

25

38

7

1

8

Negative

1

39

40

0

13

13

1

26

27

Total

21

65

86

13

38

51

8

27

35

Positive

14

34

48

10

29

39

4

5

9

Negative

6

31

37

2

9

11

4

22

26

Total

20

65

85

12

38

50

8

27

35

ADI-R+ADOS

ADI-R

ADOS

Note: ADI-R=Autism Diagnostic Interview-Revised. ADOS=Autism Diagnostic Observation
Schedule
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Table 4. Number of Individuals Identified as Positive or Negative for ASD According to the ADI-R and
ADOS
ADI-R
Full Sample
Pos.

Neg.

Males
Total

Pos.

Neg.

Females
Total

Pos.

Neg.

Total

Positive
35
13
48
30
9
39
5
4
10
27
37
7
4
11
3
23
45
40
85
37
13
50
8
27
Note: ADI-R=Autism Diagnostic Interview- Revised; ADOS=Autism Diagnostic Observation Schedule
ADOS

Negative
Total

9
26
35
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Table 5. Regression Coefficients Showing Cognitive and Language Factors as Predictors of ASD
Classification
Leiter-R
B (SE)
OR (95%
CI)
ADI-R
Full Sample
Males
Females

ADOS
Full Sample
Males
Females

Clinical
Diagnosis
Full Sample
Males
Females

B (SE)

PPVT
OR (95%
CI)

B (SE)

EVT
OR (95%
CI)

-1.03
(0.32)**
-0.96
(0.63)
-0.76
(0.44) †

0.36 (0.190.67)
0.38 (0.111.32)
0.47 (0.201.12)

-0.42
(0.13)**
-0.26 (0.25)
-0.21 (0.22)

0.66 (0.500.86)
0.77 (0.481.25)
0.81 (0.531.24)

-0.44
(0.14)**
-0.12 (0.25)
-0.48 (0.32)

0.64 (0.49.847)
0.99 (0.621.58)
0.62 (0.331.14)

-0.77
(0.24)**
-0.82
(0.66)
-0.43
(0.28)

0.46 (0.280.74)
0.44 (0.121.61)
0.65 (0.381.12)

-0.40
(0.13)**
-0.12 (0.27)
-0.24 (0.19)

0.67 (0.520.87)
0.89 (0.521.50)
0.79 (0.541.15)

-0.38
(0.13)**
-0.11 (0.26)
-0.16 (0.18)

0.69 (0.530.89)
0.89 (0.541.47)
0.86 (0.611.21)

-0.29
0.75 (0.47-1.00 (0.13) 0.91 (0.71-0.09 (0.12) 0.91 (0.72(0.23)
1.18)
-0.23 (0.25) 1.16)
0.11 (0.24) 1.15)
-0.12
0.89 (0.27-0.09 (0.19) 0.79 (0.49-0.30 (0.26) 1.12 (0.70(0.60)
2.89)
1.29)
1.79)
-0.55
0.58 (0.280.92 (0.630.74 (0.44(0.36)
1.18)
1.33)
1.23)
Note: **p < .01, †p < .09. All models adjusted for chronological age. ADI-R=Autism Diagnostic
Interview-Revised; ADOS=Autism Diagnostic Observation Schedule; PPVT=Peabody Picture
Vocabulary Test; EVT=Expressive Vocabulary Test; Leiter-R=Leiter International Performance
Scale-Revised.
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Table 6. Regression Coefficients Showing Executive Function and Behavioral Control as Predictors of
ASD Classification
Brief-P Global Executive
Composite
B (SE)
OR (95% CI)

CBCL Total Score
B (SE)

OR (95% CI)

ADI-R
Full Sample
0.01 (0.01)
1.01 (0.99-1.03)
0.02 (0.01) 1.02 (1.00-1.05)
Males
0.01 (0.01)
1.01 (0.98-1.03)
0.02 (0.19) 1.02 (0.99-1.06)
Females
0.02 (0.02)
1.02 (0.98-1.06)
0.02 (0.02) 1.02 (0.98-1.07)
ADOS
Full Sample
0.02 (0.01) † 1.02 (1.00-1.04)
0.01 (0.01) 1.01 (0.99-1.04)
Males
0.02 (0.02)
1.02 (0.99-1.05)
-0.01 (0.02) 1.00 (0.96-1.03)
Females
0.02 (0.02)
1.02 (0.98-1.06)
0.03 (0.02) 1.03 (0.99-1.07)
Clinical Diagnosis
Full Sample
0.02 (0.09)* 1.04 (1.01-1.07)
0.02 (0.01) † 1.02 (1.00-1.05)
Males
0.05 (0.02)* 1.05 (1.01-1.10)
0.02 (0.02) 1.02 (0.99-1.06)
Females
0.02 (0.02)
1.02 (0.98-1.07)
0.02 (0.02) 1.02 (0.98-1.07)
Note: *p < .05, †p < .09. All models adjusted for chronological age. BRIEF-P= Behavior
Rating Inventory of Executive Function- Preschool Version; CBCL=Child Behavior
Checklist; ADI-R= Autism Diagnostic Interview-Revised; ADOS=Autism Diagnostic
Observation Schedule;
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Figure 1. Percent of Children Meeting Criteria for ASD
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